Page last updated: 2024-11-12
pnu 142633f
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PNU 142633F: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10052962 |
| MeSH ID | M0354090 |
Synonyms (9)
| Synonym |
|---|
| pnu-142633f |
| pnu 142633f |
| 1h-2-benzopyran-6-carboxamide, 1-(2-(4-(4-(aminocarbonyl)phenyl)-1-piperazinyl)ethyl)-3,4-dihydro-n-methyl-, (1s)-, (2z)-2-butenedioate (1:1) |
| 249765-69-3 |
| pnu-142633 maleate |
| unii-vf98f3655p |
| vf98f3655p , |
| Q27291803 |
| (z)-but-2-enedioic acid;(1s)-1-[2-[4-(4-carbamoylphenyl)piperazin-1-yl]ethyl]-n-methyl-3,4-dihydro-1h-isochromene-6-carboxamide |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events associated with PNU-142633 treatment included chest pain (two patients) and QTc prolongation (three patients)." | ( Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Azie, N; Blunt, DE; Couch, JR; Cutler, NR; Diamond, S; Fleishaker, J; Goldstein, J; Gomez-Mancilla, B; Klapper, JA; Leibowitz, MT; Smith, T; Spierings, EL, 2001) | 0.31 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " At higher doses (30-100 mg) the terminal half-life was relatively constant at approximately 11 hours." | ( Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Azie, NE; Fleishaker, JC; Francom, SF; Freestone, S; Gomez-Mancilla, B; Knuth, DW; McIntosh, MJ; Pearson, LK, 1999) | 0.3 |
| "The clinical safety and pharmacokinetic data support the study of this agent as a potential treatment for migraine attacks." | ( Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Azie, NE; Fleishaker, JC; Francom, SF; Freestone, S; Gomez-Mancilla, B; Knuth, DW; McIntosh, MJ; Pearson, LK, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||